Lymph-Directed Self-Immolative Nitric Oxide Prodrug for Inhibition of Intractable Metastatic Cancer

Overview

Journal Adv Sci (Weinh)

Specialty Biomedical Engineering

Date 2022 Mar 23

PMID 35317221

Authors

Taejeong Kim

Jeeyeon Suh

Jihoon Kim

Won Jong Kim

Affiliations

Soon will be listed here.

Abstract

There has been a significant clinical demand for lymph-directed anti-metastatic therapy as tumor-draining lymph nodes play pivotal roles in cancer metastasis which accounts for more than 90% of tumor-related deaths. Despite the high potential of nitric oxide (NO) in anti-cancer therapy owing to its biocompatibility and tumor cell-specific cytotoxicity, the poor stability and lack of target specificity of present NO donors and delivery systems have limited its clinical applications. Herein, a redox-triggered self-immolative NO prodrug that can be readily conjugated to various materials containing free thiol groups such as albumin, is reported. The prodrug and its conjugates demonstrate smart release of NO donor via intramolecular cyclization under reductive conditions, followed by spontaneously generating NO in physiological conditions. The albumin-prodrug conjugate inhibits tumor metastasis by inducing cytotoxicity preferentially on tumor cells after efficiently draining into lymph nodes. This novel prodrug can contribute to the development of on-demand NO delivery systems for anti-metastatic therapy and other treatments.

Citing Articles

A multistage drug delivery approach for colorectal primary tumors and lymph node metastases.

Yuan Y, Lin Q, Feng H, Zhang Y, Lai X, Zhu M Nat Commun. 2025; 16(1):1439.

PMID: 39920155 PMC: 11806101. DOI: 10.1038/s41467-025-56768-z.

Nano-fluorescence imaging: advancing lymphatic disease diagnosis and monitoring.

Han C, Choi S, Chi S, Hong J, Cho Y, Kim J Nano Converg. 2024; 11(1):53.

PMID: 39661218 PMC: 11635084. DOI: 10.1186/s40580-024-00462-1.

Nitric oxide-based multi-synergistic nanomedicine: an emerging therapeutic for anticancer.

Tang Y, Li Q, Zhou Z, Bai H, Xiao N, Xie J J Nanobiotechnology. 2024; 22(1):674.

PMID: 39497134 PMC: 11536969. DOI: 10.1186/s12951-024-02929-z.

Fluorescent small molecule donors.

Chen G, Yu J, Wu L, Ji X, Xu J, Wang C Chem Soc Rev. 2024; 53(12):6345-6398.

PMID: 38742651 PMC: 11181996. DOI: 10.1039/d3cs00124e.

GSH-Triggered/Photothermal-Enhanced HS Signaling Molecule Release for Gas Therapy.

Liang X, Kurboniyon M, Zou Y, Luo K, Fang S, Xia P Pharmaceutics. 2023; 15(10).

PMID: 37896203 PMC: 10610203. DOI: 10.3390/pharmaceutics15102443.

References

Gad S, Park J, Park J, Fetih G, Tous S, Lee W . Enhancing Docetaxel Delivery to Multidrug-Resistant Cancer Cells with Albumin-Coated Nanocrystals. Mol Pharm. 2018; . PMC: 6064681. DOI: 10.1021/acs.molpharmaceut.7b00783. View

Zhou C, Song X, Guo C, Tan Y, Zhao J, Yang Q . Alternative and Injectable Preformed Albumin-Bound Anticancer Drug Delivery System for Anticancer and Antimetastasis Treatment. ACS Appl Mater Interfaces. 2019; 11(45):42534-42548. DOI: 10.1021/acsami.9b11307. View

Liang C, Diao S, Wang C, Gong H, Liu T, Hong G . Tumor metastasis inhibition by imaging-guided photothermal therapy with single-walled carbon nanotubes. Adv Mater. 2014; 26(32):5646-52. DOI: 10.1002/adma.201401825. View

Kim T, Suh J, Kim J, Kim W . Lymph-Directed Self-Immolative Nitric Oxide Prodrug for Inhibition of Intractable Metastatic Cancer. Adv Sci (Weinh). 2022; 9(8):2101935. PMC: 8922110. DOI: 10.1002/advs.202101935. View

Liu H, Moynihan K, Zheng Y, Szeto G, Li A, Huang B . Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014; 507(7493):519-22. PMC: 4069155. DOI: 10.1038/nature12978. View

Park D, Im S, Saravanakumar G, Lee Y, Kim J, Kim K . A cyotosol-selective nitric oxide bomb as a new paradigm of an anticancer drug. Chem Commun (Camb). 2019; 55(98):14789-14792. DOI: 10.1039/c9cc08028g. View

Tsoi K, MacParland S, Ma X, Spetzler V, Echeverri J, Ouyang B . Mechanism of hard-nanomaterial clearance by the liver. Nat Mater. 2016; 15(11):1212-1221. PMC: 5132626. DOI: 10.1038/nmat4718. View

Guirimand F, Sahut dIzarn M, Laporte L, Francillard M, Richard J, Aegerter P . Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer. Cancer Med. 2015; 4(4):532-9. PMC: 4402068. DOI: 10.1002/cam4.419. View

Kim T, Suh J, Kim W . Polymeric Aggregate-Embodied Hybrid Nitric-Oxide-Scavenging and Sequential Drug-Releasing Hydrogel for Combinatorial Treatment of Rheumatoid Arthritis. Adv Mater. 2021; 33(34):e2008793. DOI: 10.1002/adma.202008793. View

10.

Zhu G, Lynn G, Jacobson O, Chen K, Liu Y, Zhang H . Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017; 8(1):1954. PMC: 5715147. DOI: 10.1038/s41467-017-02191-y. View

11.

Oshikiri T, Takiguchi G, Miura S, Goto H, Otsubo D, Hasegawa H . Thoracic Duct Resection During Esophagectomy Does Not Contribute to Improved Prognosis in Esophageal Squamous Cell Carcinoma: A Propensity Score Matched-Cohort Study. Ann Surg Oncol. 2019; 26(12):4053-4061. DOI: 10.1245/s10434-019-07627-x. View

12.

Hoogenboezem E, Duvall C . Harnessing albumin as a carrier for cancer therapies. Adv Drug Deliv Rev. 2018; 130:73-89. PMC: 6200408. DOI: 10.1016/j.addr.2018.07.011. View

13.

Heigold S, Sers C, Bechtel W, Ivanovas B, Schafer R, Bauer G . Nitric oxide mediates apoptosis induction selectively in transformed fibroblasts compared to nontransformed fibroblasts. Carcinogenesis. 2002; 23(6):929-41. DOI: 10.1093/carcin/23.6.929. View

14.

Sung Y, Jin P, Chu L, Hsu F, Wang M, Chang C . Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat Nanotechnol. 2019; 14(12):1160-1169. DOI: 10.1038/s41565-019-0570-3. View

15.

Hu J, Xu J, Li M, Zhang Y, Yi H, Chen J . Targeting Lymph Node Sinus Macrophages to Inhibit Lymph Node Metastasis. Mol Ther Nucleic Acids. 2019; 16:650-662. PMC: 6529739. DOI: 10.1016/j.omtn.2019.04.016. View

16.

Kim J, Yung B, Kim W, Chen X . Combination of nitric oxide and drug delivery systems: tools for overcoming drug resistance in chemotherapy. J Control Release. 2016; 263:223-230. PMC: 5484762. DOI: 10.1016/j.jconrel.2016.12.026. View

17.

Schudel A, Sestito L, Thomas S . Winner of the society for biomaterials young investigator award for the annual meeting of the society for biomaterials, April 11-14, 2018, Atlanta, GA: S-nitrosated poly(propylene sulfide) nanoparticles for enhanced nitric oxide delivery to.... J Biomed Mater Res A. 2018; 106(6):1463-1475. PMC: 5924474. DOI: 10.1002/jbm.a.36348. View

18.

Sestito L, Thomas S . Lymph-directed nitric oxide increases immune cell access to lymph-borne nanoscale solutes. Biomaterials. 2020; 265:120411. PMC: 7968442. DOI: 10.1016/j.biomaterials.2020.120411. View

19.

Kim J, Saravanakumar G, Choi H, Park D, Kim W . A platform for nitric oxide delivery. J Mater Chem B. 2020; 2(4):341-356. DOI: 10.1039/c3tb21259a. View

20.

St John A, Chan C, Staats H, Leong K, Abraham S . Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater. 2012; 11(3):250-7. PMC: 3749235. DOI: 10.1038/nmat3222. View